173 related articles for article (PubMed ID: 769973)
1. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Carbone PP; Costello W
Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Johnson RO; Metter G; Wilson W; Hill G; Krementz E
Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
[TBL] [Abstract][Full Text] [Related]
3. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
[TBL] [Abstract][Full Text] [Related]
4. DTIC (NSC-45388) in malignant melanoma: a perspective.
Comis RL
Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
[No Abstract] [Full Text] [Related]
5. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
[TBL] [Abstract][Full Text] [Related]
6. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
Carmo-Pereira J; Oliveira Costa F; Pimentel P
Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
[No Abstract] [Full Text] [Related]
7. DTIC (NSC-45388) studies in the southwest oncology group.
Costanzi JJ
Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
Beretta G; Bonadonna G; Bajetta E; Tancini G; De Lena M; Azzarelli A; Veronesi U
Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
[TBL] [Abstract][Full Text] [Related]
9. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
10. [DTIC in malignant melanoma: a perspective (author's transl)].
Kokoschka EM
Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
[TBL] [Abstract][Full Text] [Related]
11. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
13. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Einhorn LH; Furnas B
Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
[TBL] [Abstract][Full Text] [Related]
15. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
[TBL] [Abstract][Full Text] [Related]
16. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Van Dyk JJ; Falkson G
Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
18. Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.
Friedman MA; Kaufman DA; Williams JE; Resser KJ; Rosenbaum EH; Cohen RJ; Glassberg AB; Blume MR; Gershow J; Chan EY
Cancer Treat Rep; 1979 Mar; 63(3):493-5. PubMed ID: 371802
[No Abstract] [Full Text] [Related]
19. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
Agrup G; Hafström L; Jönsson PE; Rorsman H
Lakartidningen; 1978 Dec; 75(49):4599-600. PubMed ID: 364213
[No Abstract] [Full Text] [Related]
20. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
